UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN) from its SEC filings: 2025 revenue $109.8 million (+21% vs the year before), net margin -140%, free cash flow -$162.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $109.8 million |
| Revenue growth | +21% |
| Net income | -$153.5 million |
| Net margin | -139.8% |
| Free cash flow | -$162.7 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +199% |
| Cash | $79.1 million |
| Long-term debt | $188.7 million |
| Share count, 1 year | +6% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.